Xianqi Y. Feng

Qingdao, 266011, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

A novel tripartite STAT5B::RARA::RP11-750B16.1 fusion in variant acute promyelocytic leukemia. Comment on: "Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia".

A novel tripartite STAT5B::RARA::RP11-750B16.1 fusion in variant acute promyelocytic leukemia. Comment on: "Novel ligand-binding domain truncated CPSF7::RARA::CPSF7 tripartite fusion confers primary ATRA resistance in atypical acute promyelocytic leukemia".

Journal: Haematologica

Published: April 21, 2026

Association between smoking status and the risk of depressive symptoms among the elderly in Shandong Province

Association between smoking status and the risk of depressive symptoms among the elderly in Shandong Province

Journal: Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi

Published: December 24, 2025

A novel splicing variant of CNTRL::FGFR1 in myeloid/lymphoid neoplasm with eosinophilia and rearrangement of FGFR1.

A novel splicing variant of CNTRL::FGFR1 in myeloid/lymphoid neoplasm with eosinophilia and rearrangement of FGFR1.

Journal: Journal of hematopathology

Published: July 09, 2025

Real-world efficacy and safety of the carfilzomib-pomalidomide-dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study.

Real-world efficacy and safety of the carfilzomib-pomalidomide-dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study.

Journal: Therapeutic advances in hematology

Published: July 08, 2025

Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.

Olverembatinib in accelerated-phase chronic myeloid leukemia: efficacy and safety evaluation.

Journal: Haematologica

Published: May 15, 2025

Comment to: "Treatment of a STAT5b::RARα positive case of APL in a patient not eligible for intensive chemotherapy".

Comment to: "Treatment of a STAT5b::RARα positive case of APL in a patient not eligible for intensive chemotherapy".

Journal: Irish journal of medical science

Published: April 12, 2025

First-in-human pharmacokinetic, safety, and preliminary efficacy studies of single- and multiple-dose FRSW117, a novel PEGylated recombinant factor VIII-Fc fusion protein with an extended half-life, in patients with severe hemophilia A.

First-in-human pharmacokinetic, safety, and preliminary efficacy studies of single- and multiple-dose FRSW117, a novel PEGylated recombinant factor VIII-Fc fusion protein with an extended half-life, in patients with severe hemophilia A.

Journal: Haematologica

Published: January 15, 2025

Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study.

Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study.

Journal: Therapeutic advances in hematology

Published: April 22, 2024

A novel study on CXXC5: unraveling its regulatory mechanisms in hematopoietic stem cell biology through proteomics and gene editing.

A novel study on CXXC5: unraveling its regulatory mechanisms in hematopoietic stem cell biology through proteomics and gene editing.

Journal: Genes & genomics

Published: March 05, 2024

Clinical efficacy of modified Yokoyama procedure with extraocular muscle transposition for high myopic eyes with restrictive esotropia

Clinical efficacy of modified Yokoyama procedure with extraocular muscle transposition for high myopic eyes with restrictive esotropia

Journal: [Zhonghua yan ke za zhi] Chinese journal of ophthalmology

Published: January 10, 2024

Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials.

Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials.

Journal: ESMO open

Published: January 12, 2023

Identification and Validation of a m5C RNA Modification-Related Gene Signature for Predicting Prognosis and Immunotherapeutic Efficiency of Gastric Cancer.

Identification and Validation of a m5C RNA Modification-Related Gene Signature for Predicting Prognosis and Immunotherapeutic Efficiency of Gastric Cancer.

Journal: Journal of oncology

Published: August 17, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026